A Phase 1 Study of the Safety and Efficacy of Gene Modified Autologous Hematopoietic Stem Cell in β-thalassemia Major

ß-thalassemia Clinical Trial

Official title:

A Phase 1 Clinical Trail of the Safety and Efficacy of BD211 Intravenous Infusion for the Treatment of Transfusion-dependent β-thalassaemia Patients

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT06465550
• Other study ID #: BD-TDT-211005
• Status: Recruiting
• Phase: Phase 1
• Start date: January 5, 2024
• Est. completion date: December 2026

Study information

• Verified date: June 2024
• Source: Shanghai BDgene Co., Ltd.
• Contact: fujun Li
• Phone: +86-19121311061
• Email: fujun.li[@]bdgene.cn
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This study will be intented to evaluate the safety, tolerability, and engraftment efficacy after myeloablative preconditioning and transplantation of autologous CD34+ hematopoietic stem cells transduced with a lentiviral vector encoding the human βA-T87Q-globin gene in patients with transfusion-dependent (TDT) β-thalassemia.

Description:

This is an open-label, single-dose study of BD211 in patients with transfusion-dependent β-thalassemia aged 3 to 35 years. It is estimated that 9 subjects will be enrolled. BD211 is a gene modified gene therapy product designed to produce healthy β-globin in red blood cells in beta-thalassemia patients. The total follow-up duration was 18 months, the safe endpoints and effectiveness endpoints will be used to assess the safety and efficacy profiles in patients with transfusion-dependent β-thalassemia.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 9
• Est. completion date: December 2026
• Est. primary completion date: December 2026
• Accepts healthy volunteers: No
• Gender: All
• Age group: 3 Years to 35 Years

Eligibility

Inclusion Criteria:

1. Participants aged 3 years (inclusive) to 18 years (exclusive), with no gender restrictions.

2. Parents/legal guardians have fully understood and voluntarily signed a written informed consent form; and it is recommended that children aged 8 and above be involved in the decision to participate in this clinical trial and obtain a written consent form.

3. Transfusion-dependent ß-thalassemia patients. "Transfusion-dependent" is defined as:

requiring at least 100 mL/kg of packed red blood cells annually; the genotype can be ß0/ß0, ß0/ß+, or ß+/ß+, diagnosed through hemoglobin studies.

4. Eligible for allogeneic hematopoietic stem cell transplantation, but without a donor or those refusing to undergo allogeneic hematopoietic stem cell transplantation.

5. Have undergone symptomatic treatment for at least the past 2 years and have retained medical records including transfusion history.

6. Stable condition and maintained an appropriate iron chelation regimen.

7. Good status of organ function.

8. Good compliance from the individual and parents/legal guardians, willing to adhere to visit schedules, trial plans, laboratory tests, and other trial procedures as stipulated in this protocol.

9. Willing to participate in long-term follow-up research.

Exclusion Criteria:

1. Has a fully HLA-matched hematopoietic stem cell donor and is willing to receive a fully HLA-matched hematopoietic stem cell transplant. Enrollment is otherwise only advised after review by the safety review committee.

2. Positive for antibodies against Human Immunodeficiency Virus 1/2 (HIV-1/HIV-2), Treponema pallidum (TP) specific antibodies, Human T-lymphotropic Virus 1 or 2 (HTLV-1/HTLV-2) antibodies, and Vesicular Stomatitis Virus G (VSV-G).

3. Positive for Hepatitis B Virus (HBV) HbsAg or HBV-DNA; Hepatitis C Virus (HCV) HCAb positive; positive nucleic acid test for Epstein-Barr Virus (EBV) or Cytomegalovirus (CMV).

4. Severe active bacterial, viral, fungal, malarial, or parasitic infections.

5. Has had, or currently has, a malignant, myeloproliferative, or immunodeficiency disorder.

6. Direct relatives with known or suspected hereditary cancer syndromes (including but not limited to breast cancer, colorectal cancer, ovarian cancer, prostate cancer, and pancreatic cancer).

7. Autoimmune diseases that could result in transfusion difficulties.

8. Major organ diseases or abnormal lab tests, including:

1. Liver cirrhosis, fibrosis, or active hepatitis, and/or abnormal liver function tests (Serum total bilirubin (TBIL) = 1.5x Upper Limit of Normal (ULN); Alanine aminotransferase (ALT) and Aspartate aminotransferase (AST) = 2.5x ULN; Alkaline phosphatase = 2.5x ULN).

2. Heart disease, or Left Ventricular Ejection Fraction (LVEF) < 60%.

3. Kidney diseases, or serum creatinine = 1.5ULN, creatinine clearance rate < 30% of the normal level (measured or calculated by the Cockcroft-Gault equation).

4. Endocrine disorders, such as insulin-dependent diabetes, hyperthyroidism, or hypothyroidism.

5. Severe iron overload, serum ferritin = 5000 ng/mL.

6. Cardiac T2* < 20 ms, and/or liver iron content (LIC) = 15mg/g liver weight by MRI.

7. Significant pulmonary hypertension diagnosed clinically according to guidelines, requiring clinical medical intervention.

9. Uncorrected bleeding disorders.

10. Severe psychiatric disorders.

11. Peripheral blood white cell (WBC) count < 3x10^9/L or platelets count < 120x10^9/L.

12. Received hydroxyurea treatment within the last 3 months before stem cell collection.

13. Used erythropoiesis-stimulating agents within the 3 months prior to HSC collection.

14. History of allogeneic transplantation.

15. Previously received any type of gene and/or cell therapy.

16. Participating in another clinical trial and is within a 30-day screening period.

17. Has contraindications to anesthesia.

18. Has contraindications to hematopoietic stem cell collection.

19. Allergic to the investigational drug or its excipients.

20. Any other conditions determined by the investigator as unsuitable for participation in this clinical trial.

Related Conditions & MeSH terms

• beta-Thalassemia
• ß-thalassemia
• Thalassemia

Intervention

Genetic:
• BD211
Genetically modified CD34+ autologous stem cells were transfused intravenously with single dosing.

Locations

Country	Name	City	State
China	Sun Yat-sen Memorial Hospital	Guangzhou	Guandong
China	The First Affiliated Hospital of Guangxi Medical University	Nanning	Guangxi
China	Shanghai Ruijin Hospital, Shanghai Jiaotong University	Shanghai	Shanghai City

Sponsors (1)

Lead Sponsor	Collaborator
Shanghai BDgene Co., Ltd.

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Mean time from BD211 treatment to successful neutrophil engraftment, as well as the number and percentage of participants with successful neutrophil engraftment.	Definition of successful neutrophil engraftment: A consistent absolute neutrophil count (ANC) recovery of =0.5×10^9/L over three consecutive days.	18 months
Primary	Mean time from BD211 treatment to successful platelet engraftment, as well as the number and percentage of participants with successful platelet engraftment.	Definition of successful platelet engraftment: No platelet transfusion for 7 days with platelet counts of =20×10^9/L in three consecutive measurements.	18 months
Primary	Proportion of participants achieving transfusion independence (TI)	TI defined as "hemoglobin (Hb) = 90g/L without any transfusion of packed red blood cells (pRBCs) for 12 months at any time during the study period after BD211 treatment"; proportion of participants with TI = number of participants with TI ÷ total number of BD211 treatment.	18 months
Secondary	BD211 transplant-related mortality (TRM) and overall survival (OS) after BD211 treatment.	TRM = number of BD211 transplant-related deaths ÷ total number of BD211 treatment x 100% OS = number of all-cause deaths after BD211 treatment ÷ total number of BD211 treatment x 100%	18 months
Secondary	Incidence of aberrant replication competent lentivirus (RCL) or malignant transformation induced by vector insertion after BD211 treatment.	RCL positivity rate = number of RCL positive cases ÷ total number of BD211 treatment × 100%.	18 months
Secondary	Total number of days hospitalized from the day of discharge after BD211 treatment to 12 months.	The number of days of all-cause hospitalisation was calculated for each participant from the start of discharge from the transplantation unit after successful neutrophil and platelet engraftment to 18 months after BD211 treatment .	18 months
Secondary	Types, numbers and incidence rate of adverse events (AEs) and serious adverse events (SAEs) that occurred within 12 months after BD211 treatment.	AEs and SAEs were evaluated per the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version 5.0.The frequency, severity, and correlation of AEs and SAEs with the investigational drug based on laboratory results and clinical manifestations were determined.	18 months
Secondary	Mean duration (days) after participants reached TI	Mean duration after reaching TI = sum of duration after reaching TI for all participants ÷ total number of participants.	18 months
Secondary	Mean time required from BD211 treatment (D0) to achieve TI	Mean time required from BD211 treatment (D0) to achieve TI = sum of time required from BD211 infusion (D0) to achieve TI ÷ total number of participants.	18 months
Secondary	Mean Hb values after BD211 treatment	Mean Hb of participants per month = sum of Hb (g/L) values of all participants per month ÷ total number of participants	12 months~18months
Secondary	Proportion of participants with 60% and 80% reduction in blood transfusions from baseline	The mean blood transfusion volume (mL/kg/year) in the 2 years prior to enrolment was used as the baseline, and compared with the mean blood transfusion volume (mL/kg/year) in the M12~M18 period after receiving the BD211 infusion, and the proportion of participants whose blood transfusion volume was reduced by 60% and 80%, respectively, was calculated.	12 months~18months
Secondary	Change in ferritin levels from baseline.	Change in mean serum ferritin levels compared to baseline values at 6 months, 12 months and 18 months after BD211 treatment.	18 months
Secondary	Expression of ßA-T87Q globin protein in whole blood	HPLC method was used to measure the expression of ßA-T87Q globin protein in peripheral blood.	18 months
Secondary	Mean VCN of the BD211 lentivirus vector in peripheral blood	qPCR method were used to measure the VCN level of the BD211 lentivirus vector in peripheral blood.	18 months
Secondary	Dose-response relationship after BD211 treatment.	The relationship between the dose of BD211 treatment and pharmacological parameters such as TI and expression of ßA-T87Q globin protein were analyzed.	18 months